Key takeaways:
- Patients who received preoperative semaglutide had lower postoperative total weight loss at 12 months compared with controls.
- Median HbA1c levels and diabetes remission at 1 year were similar between groups.
Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent metabolic and bariatric surgery, according to study results published in JAMA Surgery.